ESR1 and breast cancer: Interestingly, in a randomized clinical trial with ER/PR-negative BC patients, those treated with chemotherapy plus gonadotropin-releasing hormone agonist/analogue (GnRH-a, inhibits ovarian production of estrogens and progesterone) had a better overall survival than those treated with chemotherapy without GnRH-a [24].